What Verisante Technology does

Verisante Technology, Inc. is a publicly listed company on the TSX Venture Exchange NEX Board (symbol: VER.H) headquartered in Vancouver, British Columbia, with a small executive team of four. Founded in 2006 by Thomas Braun, the company historically developed the Aurora diagnostic device, a Class III medical device using infra-red spectroscopy licensed from the BC Cancer Agency for skin cancer detection. During its 2009-2016 operating period the company obtained ISO 13485 certification, CE Mark approval, and Health Canada Class III approval, and accumulated two US patents and one PRC patent in infra-red spectroscopy, raising approximately $24 million cumulatively.

Today Verisante operates as an acquisition shell company with no commercial products, no operating revenue, and no active product development. Its go-to-market is the sourcing and execution of Reverse Takeover (RTO) transactions on TSX-V Tier 2, targeting private technology companies seeking a public listing. The company's business model is predicated on completing an RTO acquisition, after which the combined entity would generate revenue from the acquired operations; until such a transaction closes, the company is funded only by small private placements and shares-for-debt settlements (most recently CAD $98,580 in July 2022).

The proposed RTO with SunRegen Healthcare AG — announced August 13, 2024, updated October 31, 2024, and accompanied by a CAD $2.1 million private placement at the target in December 2024 — was terminated on March 31, 2025, leaving the shell without an identified target and with no near-term operating revenue path. Distribution, marketing, and customer channels are not applicable in the current shell-company configuration.

Name

Verisante Technology

Legal name

Verisante Technology, Inc.

Website

https://verisante.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Verisante Technology is a TSX-V NEX listed public shell company (VER.H) seeking to acquire operating technology businesses via Reverse Takeover, with no current products or revenue. Historically, it developed an infra-red spectroscopy-based Class III skin cancer diagnostic device.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA) (HLACANAN)

akta.pro secondary industries

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Skin cancer diagnostics
• Infrared spectroscopy devices
• Medical device manufacturer
• Reverse takeover shell
• Public listing vehicle

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Others

Revenue model

1. Capital Raising / Private Placement: The company raises capital through non-brokered private placements of common shares. Proceeds are used for general corporate purposes, administrative expenses, and working capital. As a pre-RTO shell, the company has no operating revenue from product or service sales.
2. Acquisition / RTO Transaction Fees: Revenue model is predicated on completing an RTO acquisition of a target company, at which point the combined entity will generate revenue from the acquired business operations. No current operating revenue streams exist.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Verisante Technology currently operates as a publicly listed reverse takeover (RTO) shell company on the TSX-V NEX Board (symbol VER.H) seeking to acquire a successful technology business via RTO. Historically, the company developed Class III medical diagnostic devices using proprietary infra-red spectroscopy technology for skin cancer detection, achieving ISO 13485 certification, CE mark, and Health Canada Class III approvals. The company's leadership is actively soliciting private technology companies seeking public listing and growth capital.

Product overview

Verisante Technology, Inc. is a publicly traded acquisition company listed on the TSX Venture Exchange NEX Board (symbol: VER.H) that operates as a reverse takeover vehicle seeking to acquire successful businesses, particularly cutting-edge technology companies. Historically, the company developed a Class III diagnostic medical device using infrared spectroscopy technology that received Health Canada approval, CE mark certification, and ISO 13485 medical device manufacturer certification. The company previously licensed technology from the BC Cancer Agency and holds patents in infrared spectroscopy. Currently, Verisante is focused on identifying and acquiring businesses that meet TSX Venture Exchange Tier 2 listing requirements, with a proposed reverse takeover transaction with SunRegen Healthcare AG (terminated March 2025).

Differentiator

Problem solved

Functional benefit

Products and services

• Aurora Skin Cancer Diagnostic Device

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core and minor.

• SunRegen Healthcare AGcoreStrategic or Co-development Partner · 13 August 2024Verisante Technology proposed a Reverse Takeover (RTO) with SunRegen Healthcare AG, announced on August 13, 2024. SunRegen is a healthcare company seeking a public listing. The RTO would have resulted in SunRegen becoming a publicly traded entity through Verisante's TSX-V shell. SunRegen closed a $2.1M private placement on December 18, 2024 as part of the RTO process. The proposed transaction was subsequently updated on October 31, 2024, and ultimately terminated on March 31, 2025.
• BC Cancer AgencyminorStrategic or Co-development PartnerVerisante licensed technology from the BC Cancer Agency, which was used to develop the company's original Aurora diagnostic device for skin cancer detection.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Roche Diagnostics: Global leader in in-vitro diagnostics and oncology testing. Provides the dominant competitive context for any small-cap spectroscopy-based diagnostic device, including Verisante's Aurora.
• Abbott Laboratories: Global diagnostics and medical-device major with extensive cancer-diagnostic and molecular-testing portfolios. A broad incumbent against which Verisante's historical Aurora device would have competed for clinical adoption and reimbursement.

Direct peers

• STRATA Skin Sciences: Formerly Mela Sciences, STRATA developed and commercialized the MelaFind optical/electronic skin-lesion diagnostic device for early melanoma detection — a near-direct analogue to Verisante's discontinued Aurora infra-red spectroscopy platform for skin cancer diagnosis.
• SciBase: Swedish developer of the Nevisense electrical impedance spectroscopy system for early melanoma detection. Highly comparable to Verisante's Aurora: small-cap, single-product, spectroscopy-based skin-cancer diagnostic device company with regulatory clearances in EU/US.

Emerging players

• DermTech: US-based molecular diagnostics company focused on non-invasive skin-cancer detection via adhesive patch genomics. Comparable as a small-cap skin-cancer diagnostic developer, though using a different technology modality than Verisante's infra-red spectroscopy.
• Renishaw plc: UK-based precision engineering and spectroscopy company with Raman/in-vivo diagnostic products used in medical and research applications. Relevant because Verisante's patents are in infra-red spectroscopy and Renishaw demonstrates how a small spectroscopy-IP base can scale into adjacent diagnostic applications.
• Caliber Imaging & Diagnostics (Caliber I.D.): Developer of VivaScope confocal microscopy systems for non-invasive skin imaging, including melanoma detection. Comparable as a small specialty medical-imaging / skin-cancer diagnostic company with overlapping clinical use cases to Verisante's Aurora.
• Michelson Diagnostics: UK-based developer of the VivoSight optical coherence tomography (OCT) system for skin-cancer imaging. Comparable in scale and clinical use case (non-invasive skin-cancer diagnosis) to Verisante's historical spectroscopy-based offering.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/Verisante
• Facebookfacebook.com/verisante
• LinkedInlinkedin.com/company/verisantetechnology

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verisante Technology